Pharmicell announced on the 13th that it recorded a cumulative sales revenue of 53.8 billion won and an operating profit of 16.5 billion won in the first half of this year. This marks the company's highest performance ever on a semiannual basis.
The company noted, "Sales increased 1.8 times and operating profit grew 71 times compared to the same period last year," adding that "operating profit nearly doubled the annual record of 8.8 billion won set in 2022, just in the first half."
In the second quarter, sales rose by 50% year-on-year to 26.7 billion won, while operating profit surged by 265% to 8.1 billion won.
By institutional sector, the bio-chemical business division recorded sales of 52.6 billion won, while the bio-medical division posted sales of 1.2 billion won. Sales of low dielectric constant electronic materials in the bio-chemical division amounted to 29.5 billion won, accounting for 55% of the total, a 230% increase compared to 8.9 billion won in the same period last year.
The company stated that the rapid spread of the artificial intelligence (AI) industry has led to an explosive increase in demand for related materials, driving performance improvement. It achieved a semiannual sales of 29.7 billion won in low dielectric constant electronic materials, up from 27 billion won in the previous year. Sales of active pharmaceutical ingredients also increased by 53% year-on-year to 9.6 billion won.
Sales of mPEG (methoxy polyethylene glycol), supplied to the multinational pharmaceutical company UCB, reached 7.7 billion won in the first half, surpassing last year's annual performance of 7.6 billion won.
A Pharmicell official said, "The rapid growth of the AI industry has led to a surge in demand for advanced electronic materials, continuing robust growth in our core material business." He added, "The supply of active pharmaceutical ingredients is also expanding globally, and we expect strong performance to continue in the second half."